Skip to content
The Policy VaultThe Policy Vault

JynarqueUnited Healthcare

autosomal dominant polycystic kidney disease (ADPKD)

Initial criteria

  • Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)

Reauthorization criteria

  • Documentation of positive clinical response to Jynarque therapy

Approval duration

12 months